1. Search Result
Search Result
Results for "

Tesirine

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

5

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128952
    Tesirine
    3 Publications Verification

    SG3249

    Drug-Linker Conjugates for ADC DNA Alkylator/Crosslinker Cancer
    Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .
    Tesirine
  • HY-24144

    DNA Alkylator/Crosslinker Cancer
    Tesirine intermediate-2 is the intermediate of Tesirine (HY-128952). Tesirine (SG3249), a pyrrole benzodiazepine (PBD) dimer, is a DNA small channel crosslinker with strong cytotoxicity. Tesirine can be used to synthesize Antibody-Drug Conjugates (ADCs), the warhead component of the payload is SG3199 (HY-101161), which has strong anticancer cell activity.
    Tesirine intermediate-2
  • HY-47820

    DNA Alkylator/Crosslinker Cancer
    Tesirine intermediate-1 is the intermediate of Tesirine (HY-128952). Tesirine (SG3249), a pyrrole benzodiazepine (PBD) dimer, is a DNA small channel crosslinker with strong cytotoxicity. Tesirine can be used to synthesize Antibody-Drug Conjugates (ADCs), the warhead component of the payload is SG3199 (HY-101161), which has strong anticancer cell activity.
    Tesirine intermediate-1
  • HY-132257

    SC-002

    Antibody-Drug Conjugates (ADCs) Notch Cancer
    Rovalpituzumab tesirine (SC-002) is an antibody-drug conjugate (ADC) with anticancer effects. Rovalpituzumab tesirine contains a DLL3-targeting antibody Rovalpituzumab (HY-P99043) tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. Rovalpituzumab tesirine can be used for the stduy of small cell lung cancer (SCLC) .
    Rovalpituzumab tesirine
  • HY-P99349

    Loncastuximab Tesirine-lpyl; ADCT-402

    Antibody-Drug Conjugates (ADCs) Apoptosis Cancer
    Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). The antibody portion is Loncastuximab (HY-P99711), and the drug-linker conjugate for ADC is Tesirine (HY-128952). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .
    Loncastuximab tesirine
  • HY-101152

    Drug-Linker Conjugates for ADC Cancer
    SG3199-Val-Ala-PAB is an intermediate of Tesirine synthesis. Tesirine is a agent-linker conjugate for ADC which can be used for the research of several cancers .
    SG3199-Val-Ala-PAB
  • HY-132252

    MP-PEG8-Val-Ala-PABC; MP-PEG8-VA-PABC

    ADC Linker Cancer
    Mal-PEG8-Val-Ala-PABC is a cleavable Tesirine linker used in the synthesis of Tesirine, a agent-linker conjugate for ADC .
    Mal-PEG8-Val-Ala-PABC
  • HY-101161
    SG3199
    2 Publications Verification

    DNA Alkylator/Crosslinker ADC Payload Cancer
    SG3199 is a cytotoxic DNA minor groove interstrand crosslinking pyrrolobenzodiazepine (PBD) dimer. SG3199 is the released warhead component of the ADC payload Tesirine (SG3249) .
    SG3199
  • HY-141599

    ADCT 301

    Antibody-Drug Conjugates (ADCs) Interleukin Related Cancer
    Camidanlumab tesirine (ADCT 301) is an ADC comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines .
    Camidanlumab tesirine
  • HY-164730

    ADCT-602; hLL2-Cys-PBD

    Antibody-Drug Conjugates (ADCs) Cancer
    Epratuzumab Tesirine (ADCT-602) is a novel CD22-targeted ADC. Epratuzumab Tesirine contains a PBD dimer and a payload SG3249 .
    Epratuzumab Tesirine
  • HY-P99043
    Rovalpituzumab
    1 Publications Verification

    Notch Cancer
    Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .
    Rovalpituzumab
  • HY-147095

    Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Val-Ala-PABC-Exatecan is a Drug-Linker Conjugates for ADC,consiting of a cleavable Tesirine linker (Val-Ala-PABC) and Exatecan (topoisomerase I inhibitor,HY-13631). Val-Ala-PABC-Exatecan can be used for ADC molecues synthesis,such as Mal-PEGn-amide-va-Exatecan .
    Val-Ala-PABC-Exatecan
  • HY-147095A

    Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Val-Ala-PABC-Exatecan trifluoroacetate is a Drug-Linker Conjugates for ADC, consiting of a cleavable Tesirine linker (Val-Ala-PABC) and Exatecan (topoisomerase I inhibitor, HY-13631). Val-Ala-PABC-Exatecan trifluoroacetate can be used for ADC molecues synthesis, such as Mal-PEGn-amide-va-Exatecan .
    Val-Ala-PABC-Exatecan trifluoroacetate
  • HY-W076556

    ((Allyloxy)carbonyl)-L-valyl-L-alanine

    Biochemical Assay Reagents Others
    Alloc-Val-Ala-OH (((Allyloxy)carbonyl)-L-valyl-L-alanine) is a building block in the synthesis of Tesirine, a clinical antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. The Val-Ala will specifically be cleaved by Cathepsin B. The Alloc group is stable to treatment with piperidine and TFA, but can be easily removed under mild conditions by palladium catalyzed allyl transfer.
    Alloc-Val-Ala-OH
  • HY-P99233

    HuMax-TAC

    ADC Antibody Transmembrane Glycoprotein Interleukin Related Cancer
    Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Camidanlumab
  • HY-P99711

    RB4v1.2

    CD19 ADC Antibody Cancer
    Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349) .
    Loncastuximab
  • HY-175004

    ADC Payload DNA Alkylator/Crosslinker Cancer
    PBD dimer-4 (Compound 7) is a C1-subsitituted PBD dimer. PBD dimer-4 has high DNA-binding affinity, DNA cross-linking ability and potent cytotoxicity against MDA-MB-231 cells (IC50: 236 nM). PBD dimer-4 can be used as a payload of ADC Loncastuximab tesirine (HY-P99349) to treat several different cancer types .
    PBD dimer-4
  • HY-159072

    Drug-Linker Conjugates for ADC Cancer
    Mal-Val-Ala-PAB-N(SO2Me)-Exatecan (Compound LE14) is a conjugate of an ADC toxin Exatecan (HY-13631) and a linker Mal-Val-Ala-PAB-N(SO2Me). Mal-Val-Ala-PAB-N(SO2Me)-Exatecan can be used for synthesis of ADC FZ-AD005. FZ-AD005 is a delta-like ligand 3 (DLL3, KD=58.3 pM) targeting ADC, that exhibits antitumor efficacy against SCLC cancer .
    Mal-Val-Ala-PAB-N(SO2Me)-Exatecan

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: